JP2008537482A5 - - Google Patents

Download PDF

Info

Publication number
JP2008537482A5
JP2008537482A5 JP2008501054A JP2008501054A JP2008537482A5 JP 2008537482 A5 JP2008537482 A5 JP 2008537482A5 JP 2008501054 A JP2008501054 A JP 2008501054A JP 2008501054 A JP2008501054 A JP 2008501054A JP 2008537482 A5 JP2008537482 A5 JP 2008537482A5
Authority
JP
Japan
Prior art keywords
amino acid
protein
nucleic acid
virus
acid substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008501054A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008537482A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/009010 external-priority patent/WO2006099360A2/en
Publication of JP2008537482A publication Critical patent/JP2008537482A/ja
Publication of JP2008537482A5 publication Critical patent/JP2008537482A5/ja
Pending legal-status Critical Current

Links

JP2008501054A 2005-03-10 2006-03-09 メタニューモウイルス株、およびワクチン製剤におけるその使用および抗原配列発現用ベクターとしてのその使用、ならびにウイルスの増殖法 Pending JP2008537482A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66073505P 2005-03-10 2005-03-10
PCT/US2006/009010 WO2006099360A2 (en) 2005-03-10 2006-03-09 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus

Publications (2)

Publication Number Publication Date
JP2008537482A JP2008537482A (ja) 2008-09-18
JP2008537482A5 true JP2008537482A5 (enExample) 2009-04-30

Family

ID=36992353

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008501054A Pending JP2008537482A (ja) 2005-03-10 2006-03-09 メタニューモウイルス株、およびワクチン製剤におけるその使用および抗原配列発現用ベクターとしてのその使用、ならびにウイルスの増殖法

Country Status (8)

Country Link
US (2) US20060216700A1 (enExample)
EP (1) EP1869225A4 (enExample)
JP (1) JP2008537482A (enExample)
KR (1) KR20070110924A (enExample)
CN (1) CN101548009A (enExample)
AU (1) AU2006223138B2 (enExample)
CA (1) CA2600484A1 (enExample)
WO (1) WO2006099360A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA93981C2 (ru) 2001-01-19 2011-03-25 Вироновативе Б.B. Вирус, который вызывает заболевание дыхательных путей у чувствительных k этому млекопитающих
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
CA2477235A1 (en) 2002-02-21 2003-09-04 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
CA2494485A1 (en) * 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
US20080213749A1 (en) * 2007-03-02 2008-09-04 Melanie Feola Compositions and methods for detecting human metapneumovirus
EP2069485A4 (en) * 2007-07-13 2011-05-25 Medimmune Llc PREPARATION OF NEGATIVE STRAND RNA VIRUSES BY ELECTROPORATION
WO2009062532A1 (en) * 2007-11-16 2009-05-22 Vironovative Bv Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
US20090186050A1 (en) * 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
GB0809881D0 (en) * 2008-05-30 2008-07-09 Genomica Sau Method for detecting respiratory viral agents in a test sample
PL3067064T3 (pl) 2008-12-09 2020-11-02 Novavax, Inc. Zmodyfikowane białka f rsv i sposoby ich wykorzystania
CN103977394B (zh) * 2009-07-17 2016-03-09 翰林大学校产学协力团 包含脂质体包胶的寡核苷酸和表位的免疫刺激性组合物
SMT202400297T1 (it) 2013-03-13 2024-09-16 The United States Of America As Represented By The Secretary Department Of Health And Human Services Proteine f del rsv pre-fusione e loro uso
CL2014003373A1 (es) * 2014-12-11 2015-04-10 Univ Pontificia Catolica Chile Anticuerpos monoclonales especificos para el antígeno m del virus metapneumovirus humano (hmpv), producidos y secretados por hibridomas celulares , útiles para la deteccion y el diagnostico de la infeccion causada por hmpv.
CN109069611B (zh) 2016-03-29 2022-11-04 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途
CN106282407A (zh) * 2016-08-11 2017-01-04 青岛易邦生物工程有限公司 一种b亚群禽肺病毒疫苗的效检方法
CA3043790A1 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
CN109628413A (zh) * 2018-12-29 2019-04-16 广东和信健康科技有限公司 一种人偏肺病毒的培养方法及其产物和应用
CN120022355A (zh) * 2023-11-22 2025-05-23 长春百克生物科技股份公司 一种mRNA疫苗及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
US6180398B1 (en) * 1996-07-12 2001-01-30 Virogeneitics Corporation Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
US7192593B2 (en) * 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US20020019891A1 (en) * 1999-12-30 2002-02-14 James Morrow Generic device controller unit and method
JP2002025374A (ja) 2000-07-07 2002-01-25 Matsushita Electric Ind Co Ltd Ｅｌシート及びこれを用いたスイッチ
UA93981C2 (ru) * 2001-01-19 2011-03-25 Вироновативе Б.B. Вирус, который вызывает заболевание дыхательных путей у чувствительных k этому млекопитающих
US20030232061A1 (en) * 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
CA2477235A1 (en) * 2002-02-21 2003-09-04 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US20060216824A1 (en) * 2003-01-31 2006-09-28 Tsuyoshi Tokusumi Paramyxovirus vector encoding ribozyme and utilization thereof
JP2007524372A (ja) * 2003-02-28 2007-08-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 組換えヒトメタニューモウイルスおよびその使用
CA2523657A1 (en) * 2003-04-25 2005-03-31 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
JP2007525178A (ja) * 2003-04-25 2007-09-06 メッドイミューン バクシーンズ，インコーポレイティド メタニューモウイルス株、そのワクチン製剤における用途、抗原性配列の発現のためのベクターとしての用途、並びにウイルス増殖方法
US20040229219A1 (en) * 2003-04-30 2004-11-18 Gallaher William R. Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)

Similar Documents

Publication Publication Date Title
JP2008537482A5 (enExample)
St-Jean et al. Human respiratory coronavirus OC43: genetic stability and neuroinvasion
Ivanov et al. Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase
Meyer et al. Endogenous retroviruses: with us and against us
Stobart et al. Chimeric exchange of coronavirus nsp5 proteases (3CLpro) identifies common and divergent regulatory determinants of protease activity
Moore et al. Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2
Harris et al. Interaction of poliovirus polypeptide 3CDpro with the 5 ‘and 3 ‘termini of the poliovirus genome. Identification of viral and cellular cofactors needed for efficient binding.
Yamada et al. Proteolytic activation of the spike protein at a novel RRRR/S motif is implicated in furin-dependent entry, syncytium formation, and infectivity of coronavirus infectious bronchitis virus in cultured cells
Chan et al. Complete nucleotide sequences of Nipah virus isolates from Malaysia
Scobey et al. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus
Shi et al. Bunyamwera orthobunyavirus glycoprotein precursor is processed by cellular signal peptidase and signal peptide peptidase
Nedialkova et al. Biochemical characterization of arterivirus nonstructural protein 11 reveals the nidovirus-wide conservation of a replicative endoribonuclease
Ziebuhr et al. Human coronavirus 229E papain-like proteases have overlapping specificities but distinct functions in viral replication
ATE478944T1 (de) Zytokin ligand zur behandlung von asthma und atemwegsüberreaktivität
JP2006149395A5 (enExample)
Mangel et al. Specific interactions of the adenovirus proteinase with the viral DNA, an 11-amino-acid viral peptide, and the cellular protein actin
DE602004031642D1 (de) Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine
GB2409274A (en) Trap-tagging: a novel method for the identification and purification of RNA-protein complexes
Chow et al. Adenovirus-mediated expression of the C-terminal domain of SARS-CoV spike protein is sufficient to induce apoptosis in Vero E6 cells
JP2008545393A5 (enExample)
Barretto et al. Deubiquitinating activity of the SARS-CoV papain-like protease
Lu et al. Spike gene deletion quasispecies in serum of patient with acute MERS‐CoV infection
WO2007064844A3 (en) Anti-viral griffithsin compounds, compositions, and methods of use
JP2004527239A5 (enExample)
Sohrab et al. In silico prediction and designing of potential siRNAs to be used as antivirals against SARS-CoV-2